Welcome back to Endpoints Weekly! The big news this week was the FDA’s approval of Revolution Medicines’ pancreatic cancer treatment Rasonque. The drug stunned researchers and spurred excitement in April ...
August 29, 2026 06:00 AM EDT
Weekly
Landmark approval for pancreatic cancer; Reactions to Lilly’s Phase 1 secrecy; and more
Nicole DeFeudis
Welcome back to Endpoints Weekly! The big news this week was the FDA’s approval of Revolution Medicines’ pancreatic cancer treatment Rasonque. The drug stunned researchers …
Rasonque’s speedy approval — just a month after a completed submission — represents a paradigm shift for a notoriously deadly…
Ajaz Khan, M.D., a medical oncologist at City of Hope Chicago, was in the packed audience at this summer’s American Society of…
Suneel Kamath, MD, knows too well the sense of helplessness that comes with living through what he calls “the doughnut…
Why did a presentation on Revolution Medicines' pancreatic cancer drug get a standing ovation? Why did biotech stocks perform so…
Following dynamite data that earned a standing ovation at the American Society of Clinical Oncology meeting in May, Revolution…
Eli Lilly announces two China deals, Akeso's lung cancer bispecific payoff, and more biotech news from The Readout
Revolution drug heralded as a pancreatic cancer breakthrough cleared by FDA
As RevMed preps for ‘historic’ pancreatic cancer launch, questions linger on the ground
FDA greenlights Revolution Medicines' pancreatic cancer gamechanger
FDA approves new pancreatic cancer drug expected to usher in new era of treatment
Pharmalittle: We're reading about a pancreatic cancer drug approval, a Trump deal with biotechs, and more
Revolution Medicines gets FDA nod for targeted pancreatic cancer drug | CNN
Groundbreaking treatments and vaccines offer hope in fight against cancer
FDA Approves Pancreatic Cancer Drug That Could Double Survival Time—What To Know About Rasonque
FDA approves Revolution Medicines' daraxonrasib for pancreatic cancer
U.S. approves breakthrough pancreatic cancer drug, heralding a new era for an intractable disease
